Provided by Tiger Trade Technology Pte. Ltd.

Urogen Pharma Ltd.

43.62
-1.8800-4.13%
Post-market: 43.620.00000.00%19:59 EDT
Volume:580.05K
Turnover:25.51M
Market Cap:2.12B
PE:-22.14
High:45.54
Open:45.09
Low:43.39
Close:45.50
52wk High:50.81
52wk Low:15.86
Shares:48.68M
Float Shares:43.35M
Volume Ratio:0.86
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9700
EPS(LYR):-3.1901
ROE:-1481.26%
ROA:-18.06%
PB:-16.04
PE(LYR):-13.67

Loading ...

UroGen Pharma initiated with a Buy at Jefferies

TIPRANKS
·
Apr 10

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 31

UroGen Pharma publishes results from ENVISION trial of Zusduri

TIPRANKS
·
Mar 30

UroGen says ZUSDURI shows 72.2% event-free rate at 24 months in ENVISION trial

Reuters
·
Mar 30

UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report

TIPRANKS
·
Mar 13

Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Mar 07

UroGen Pharma Grants Inducement RSUs Covering Up to 51,200 Shares

Reuters
·
Mar 07

UroGen’s ZUSDURI Data And Reimbursement Progress Shift Risk Reward Profile

Simply Wall St.
·
Mar 05

Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk

TIPRANKS
·
Mar 03

Stock Track | UroGen Pharma Soars 7.78% After-Hours on Improved Earnings, Revenue Growth and Favorable Loan Refinancing

Stock Track
·
Mar 03

UroGen Falls on 4Q Results Miss, Debt Refinancing

Dow Jones
·
Mar 03

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 02

Stock Track | Urogen Pharma Plummets 5.94% Intraday Following Q4 Earnings Miss

Stock Track
·
Mar 02

Urogen Pharma Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 02

UroGen Pharma Q4 revenue misses; forecasts FY operating expenses $240 mln-$250 mln

Reuters
·
Mar 02

Earnings Flash (URGN) UroGen Pharma Posts Q4 Net Loss $0.54 a Share, vs. FactSet Est of $0.50 Loss

MT Newswires Live
·
Mar 02

UroGen FY 2025 revenue USD 109.8 million up 21%

Reuters
·
Mar 02

UroGen Pharma Q4 EPS $(0.54) Misses $(0.53) Estimate, Sales $37.837M Miss $39.922M Estimate

Benzinga Earnings
·
Mar 02

UroGen Pharma Refinances Term Loan With Pharmakon Advisors at $250 Million Facility

Reuters
·
Mar 02

UroGen reports durable ZUSDURI complete responses across EORTC risk groups in ENVISION trial analysis

Reuters
·
Feb 27